Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Microrna. 2024;13(3):202-210. doi: 10.2174/0122115366286360240625095932.
Molecular markers in Colorectal Cancer (CRC) are needed for more accurate classification and personalized treatment. In this way, we investigated the effects of the gene on clinical outcomes of its expression fluctuations and its polymorphism at rs1267623 in CRC.
In this study, 36.36 percent of patients with CRC were women, and 63.63 percent were men. After the pathology department confirmed the tumor of the samples, the stage and grade of the tumor were determined according to the TNM system. Real-time PCR was used to check the expression of the gene in tumor and non-tumor tissues, and its polymorphism in rs1267623 was also checked using the Tetra-ARMs PCR technique.
The expression of in tumor tissues was significantly higher than in non-tumoral tissues (P = 0.001), indicating an upregulation of gene expression in tumoral tissues. The user's text is empty. Furthermore, there was a significant correlation between expression and tumor stage ( = 0.001), as well as tumor grade ( = 0.003). However, no significant link was found between lymph node metastasis and distant metastasis of gene expression ( = 0.3). Additionally, no mutation was detected in the investigation of rs1267623 polymorphism.
The gene was upregulated in tumoral tissues. Remarkably, no mutation was found in the rs1267623 polymorphism. As a result, this gene can be used as a biomarker in the diagnosis and treatment of CRC.
结直肠癌（CRC）需要分子标志物来进行更准确的分类和个性化治疗。为此，我们研究了基因表达波动及其在 CRC 中 rs1267623 多态性对临床结局的影响。
本研究中，CRC 患者女性占 36.36%，男性占 63.63%。在病理科确认样本肿瘤后，根据 TNM 系统确定肿瘤的分期和分级。采用实时 PCR 检测肿瘤和非肿瘤组织中基因的表达，采用 Tetra-ARMs PCR 技术检测 rs1267623 多态性。
肿瘤组织中基因的表达明显高于非肿瘤组织（P=0.001），提示基因在肿瘤组织中表达上调。基因表达与肿瘤分期（=0.001）和肿瘤分级（=0.003）显著相关。然而，基因表达与淋巴结转移和远处转移之间无显著关联（=0.3）。此外，在 rs1267623 多态性研究中未发现突变。
基因在肿瘤组织中表达上调。值得注意的是，在 rs1267623 多态性研究中未发现突变。因此，该基因可作为 CRC 诊断和治疗的生物标志物。
